Home/Pipeline/CB-020

CB-020

Solid Tumors

PreclinicalResearch

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Research

Company

Caribou Biosciences

About Caribou Biosciences

Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is a clinical-stage biotech focused on developing allogeneic CAR-T cell therapies using its proprietary chRDNA genome-editing platform. The company's mission is to create readily available, 'off-the-shelf' cell therapies that address the manufacturing complexities, high costs, and delays associated with personalized autologous treatments. Its strategy centers on 'armoring' these therapies through multiplex gene editing to enhance persistence and activity, with multiple Phase 1 clinical trials underway for B-cell non-Hodgkin lymphoma and multiple myeloma. Caribou aims to translate its foundational CRISPR science into transformative medicines for hematologic cancers.

View full company profile

Therapeutic Areas

Oncology Hematologic Malignancies

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed